Quarterly ResultMay 4, 2026, 04:15 PM
GeneDx Q1 Revenue $102.3M; Cuts Full-Year Guidance to $475-490M
AI Summary
GeneDx Holdings Corp. reported Q1 2026 financial results, with revenue increasing 17% year-over-year to $102.3 million and exome and genome volume growing 34%. However, the company posted an adjusted net loss of $8.2 million compared to a profit in the prior year. GeneDx also updated its full-year 2026 guidance, lowering its revenue outlook to $475-$490 million and adjusting exome and genome volume growth expectations. The company highlighted strategic expansions, including new partnerships and Medicaid coverage, and advancements in innovation and clinical leadership.
Key Highlights
- Q1 2026 revenue grew 17% year-over-year to $102.3 million.
- Exome and genome test volume increased 34% year-over-year to 27,488.
- Reported an adjusted net loss of $8.2 million for Q1 2026.
- Updated full-year 2026 revenue guidance to $475-$490 million, down from $540-$555 million.
- Updated full-year 2026 exome and genome volume growth guidance to at least 30%.
- Cash, cash equivalents, and marketable securities totaled $171.7 million as of March 31, 2026.
- Expanded Medicaid coverage in Texas, Maine, and Arkansas, adding 4.9 million patients.